302 related articles for article (PubMed ID: 1332587)
41. Activity of gatifloxacin against strains resistant to ofloxacin and ciprofloxacin and its ability to select for less susceptible bacterial variants.
Fung-Tomc J; Gradelski E; Huczko E; Minassian B; Bonner DP
Int J Antimicrob Agents; 2001 Jul; 18(1):77-80. PubMed ID: 11463531
[TBL] [Abstract][Full Text] [Related]
42. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R
Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202
[TBL] [Abstract][Full Text] [Related]
43. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
King A; Phillips I
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
[TBL] [Abstract][Full Text] [Related]
44. Antimicrobial activity of DV-7751a, a new fluoroquinolone.
Tanaka M; Hoshino K; Ishida H; Sato K; Hayakawa I; Osada Y
Antimicrob Agents Chemother; 1993 Oct; 37(10):2112-8. PubMed ID: 8257132
[TBL] [Abstract][Full Text] [Related]
45. In vitro activity of AT-4140 against clinical bacterial isolates.
Kojima T; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1989 Nov; 33(11):1980-8. PubMed ID: 2558617
[TBL] [Abstract][Full Text] [Related]
46. In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency.
Huband MD; Cohen MA; Meservey MA; Roland GE; Yoder SL; Dazer ME; Domagala JM
Antimicrob Agents Chemother; 1993 Dec; 37(12):2563-70. PubMed ID: 8109918
[TBL] [Abstract][Full Text] [Related]
47. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
[TBL] [Abstract][Full Text] [Related]
48. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969).
Espinoza AM; Chin NX; Novelli A; Neu HC
Antimicrob Agents Chemother; 1988 May; 32(5):663-70. PubMed ID: 3293524
[TBL] [Abstract][Full Text] [Related]
49. In vitro and in vivo activities of a new quinolone, WIN 57273, possessing potent activity against gram-positive bacteria.
Sedlock DM; Dobson RA; Deuel DM; Lesher GY; Rake JB
Antimicrob Agents Chemother; 1990 Apr; 34(4):568-75. PubMed ID: 2344163
[TBL] [Abstract][Full Text] [Related]
50. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
Arpi M; Gahrn-Hansen B; Søgaard P; Bentzon MW
Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
[TBL] [Abstract][Full Text] [Related]
51. In vitro activity of temafloxacin against gram-negative bacteria: an overview.
Hardy DJ
Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890
[TBL] [Abstract][Full Text] [Related]
52. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
53. In vitro activity of BAY 12-8039, a new fluoroquinolone.
Woodcock JM; Andrews JM; Boswell FJ; Brenwald NP; Wise R
Antimicrob Agents Chemother; 1997 Jan; 41(1):101-6. PubMed ID: 8980763
[TBL] [Abstract][Full Text] [Related]
54. In-vitro and in-vivo activities of T-3262, a new pyridone carboxylic acid.
Takahata M; Otsuki M; Nishino T
J Antimicrob Chemother; 1988 Aug; 22(2):143-54. PubMed ID: 3182417
[TBL] [Abstract][Full Text] [Related]
55. The in-vitro activity of temafloxacin compared with other antimicrobial agents.
King A; Bethune L; Phillips I
J Antimicrob Chemother; 1991 Jun; 27(6):769-79. PubMed ID: 1657855
[TBL] [Abstract][Full Text] [Related]
56. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
Ismaeel NA; Tayeb OS
Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
[TBL] [Abstract][Full Text] [Related]
57. Antibacterial activity of a new tetracyclic quinolone, No. 5290, against norfloxacin- and ciprofloxacin-resistant strains of Staphylococcus aureus.
Kotera Y; Inoue Y; Ohashi M; Ito K; Tsukamoto G
Chem Pharm Bull (Tokyo); 1991 Oct; 39(10):2644-6. PubMed ID: 1666861
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
[TBL] [Abstract][Full Text] [Related]
59. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
[TBL] [Abstract][Full Text] [Related]
60. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates.
Sato K; Hoshino K; Tanaka M; Hayakawa I; Osada Y
Antimicrob Agents Chemother; 1992 Jul; 36(7):1491-8. PubMed ID: 1324647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
